Shanghai Wibson Biotechnology: difference between revisions
Diff·revision 32 → 33·05:50, 21 Jun 2025
Difference between revision 32 and revision 33 of Shanghai Wibson Biotechnology. 3 lines changed; the page grew by 444 bytes.
| Revision 32 — 13:16, 13 Jun 2025 TallySheetTad (talk) add citation for the incidence figure 6,918 bytes +103 | Revision 33 — 05:50, 21 Jun 2025 COA_Colwyn (talk) add hatnote 7,362 bytes +444 | ||
|---|---|---|---|
| 53 | Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties.{{r|reports}} | 53 | Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties.{{r|reports}} |
| 54 | 54 | ||
| + | 55 | The absence of water figures on the accompanying certificates is the substantive documentation gap in this set: a purity figure alone constrains the ''relative'' composition of what dissolved and says nothing about how much peptide the vial held.{{r|usp1503}} As elsewhere, samples were purchaser-selected rather than [[Blind sampling|blind-drawn]], so the reports cannot be read as a sample of output.{{r|reports}} | |
| + | 56 | ||
| 55 | == References == | 57 | == References == |
| 56 | {{reflist}} | 58 | {{reflist}} |
| ⋮ | ⋮ | ||
| 68 | * [[Peptide content]] | 70 | * [[Peptide content]] |
| 69 | * [[Research use only]] | 71 | * [[Research use only]] |
| + | 72 | * [[Peptide supply chain]] | |
| 70 | 73 | ||
| 71 | {{DEFAULTSORT:Shanghai Wibson Biotechnology}} | 74 | {{DEFAULTSORT:Shanghai Wibson Biotechnology}} |